A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Clinical trial NCT02293980 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT02293980

Sponsor

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2014-11-25

Primary completion

2017-01-31

Enrollment

110

View on ClinicalTrials.gov